June 2018 (Vol. 39, No. 06)
Optimal management of psoriasis symptoms falls short for about three in 10 patients with moderate plaque psoriasis and for one in five with severe psoriasis, a recent study shows.
Immune responses to the latest shingles vaccine (Shingrix) last for at least three years following vaccination. The robust immune responses develop and persist in all age groups, according to a recent study in The Journal of Infectious Diseases.
Study shows no significant difference in herpes zoster risk between psoriasis patients receiving systemic therapy and those not receiving systemic therapy.
Advertisement
Advertisement
Trending on Dermatology Times
1
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Quality of Life in CSU Shaped by More Than Skin Symptoms
5